complete targeting of peripheral blood t cells was achieved with 1 mg of moab in the nonleukemic patients ( wbc less than 10,000/microl ) , and free , bioavailable antibody was present at the next ( 10-mg ) dose level .
C0229664
peripheral blood
C0023516
wbc